Citadel Advisors
RAPP

Citadel Advisors’s Rapport Therapeutics RAPP Stock Holding History

Citadel Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,900
Closed -$513K – 14499
2025
Q4 		$513K Sell
16,900
-17,700
-51% -$490K ﹤0.01% 8967
2025
Q3 		$1.03M Buy
+34,600
New +$617K ﹤0.01% 7486
2025
Q2 		– Sell
-2,000
Closed -$20.1K – 15553
2025
Q1 		$20.1K Buy
+2,000
New +$26K ﹤0.01% 13140

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Citadel Advisors's RAPP Position: Q2 2026 in Review

Citadel Advisors opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 82,442 shares worth $3.44M. The stake represents ﹤0.01% of the portfolio and ranks #5416 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in RAPP as recently as Q4 2025.

Citadel Advisors first reported a position in RAPP in Q2 2024 and has held it in 7 quarters since. The position peaked at $13.2M in Q2 2024. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Citadel Advisors held 82,442 shares of Rapport Therapeutics worth $3.44M as of Q2 2026.
  • Rapport Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5416 holding.
  • Citadel Advisors first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Citadel Advisors's Rapport Therapeutics position peaked at $13.2M in Q2 2024.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.